Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Biweekly Oxaliplatin and Irinotecan Chemotherapy in Advanced Gastric Cancer. A First-line Multicenter Phase II Trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)

E. WÖLL, T. KÜHR, W. EISTERER, K. GATTRINGER, R. GREIL, A. ZABERNIGG, W. HILBE and J. THALER
Anticancer Research September 2008, 28 (5B) 2901-2905;
E. WÖLL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: e.woell@krankenhaus-zams.at
T. KÜHR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. EISTERER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. GATTRINGER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. GREIL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. ZABERNIGG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W. HILBE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. THALER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background: The aim of the study was to evaluate the feasibility and efficacy of an outpatient oxaliplatin/irinotecan chemotherapy in chemonaive patients suffering from unresectable gastric cancer. Materials and Methods: Biweekly oxaliplatin (85 mg/m2) and irinotecan (125 mg/m2) was chosen since it has been shown previously in colorectal cancer that oxaliplatin (85 mg/m2) is superior to a lower dose and toxicity of irinotecan is much lower if given fractionated. The irinotecan dose below the maximum tolerated dose takes into consideration concerns about increased toxicity in gastric cancer patients. Results: Fourty-three patients with histologically proven gastric adenocarcinoma and no previous palliative chemotherapy were selected. WHO grade 3 and 4 toxicities included neutropenia in 2/43 patients, anemia in 3/43 patients, nausea in 2/43 patients and diarrhea in 4/43 patients. Response rates were assessable in 38 patients as follows: complete response in three patients (8%), partial response in 19 (50%), stable disease in 11 (29%), and progressive disease in 5 patients (13%). The median time-to-progression was 5.3 months and median overall survival was 9.5 months. Conclusion: The outpatient combination of biweekly oxaliplatin/irinotecan was well tolerated and showed a response rate within the range of other first-line combination therapies. The favorable toxicity profile, however, renders oxaliplatin/irinotecan as an alternative first-line regimen.

  • Gastric cancer
  • chemotherapy
  • oxaliplatin
  • irinotecan

Footnotes

  • Received May 28, 2008.
  • Revision received July 15, 2008.
  • Accepted August 4, 2008.
  • Copyright© 2008 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research: 28 (5B)
Anticancer Research
Vol. 28, Issue 5B
September-October 2008
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Biweekly Oxaliplatin and Irinotecan Chemotherapy in Advanced Gastric Cancer. A First-line Multicenter Phase II Trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Biweekly Oxaliplatin and Irinotecan Chemotherapy in Advanced Gastric Cancer. A First-line Multicenter Phase II Trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
E. WÖLL, T. KÜHR, W. EISTERER, K. GATTRINGER, R. GREIL, A. ZABERNIGG, W. HILBE, J. THALER
Anticancer Research Sep 2008, 28 (5B) 2901-2905;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Biweekly Oxaliplatin and Irinotecan Chemotherapy in Advanced Gastric Cancer. A First-line Multicenter Phase II Trial of the Arbeitsgemeinschaft Medikamentöse Tumortherapie (AGMT)
E. WÖLL, T. KÜHR, W. EISTERER, K. GATTRINGER, R. GREIL, A. ZABERNIGG, W. HILBE, J. THALER
Anticancer Research Sep 2008, 28 (5B) 2901-2905;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates
  • Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3
  • Oxaliplatin, Irinotecan and Cetuximab in Advanced Gastric Cancer. A Multicenter Phase II Trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT)
  • Google Scholar

More in this TOC Section

  • Low-dose Apalutamide in Non-metastatic Castration-resistant Prostate Cancer: A Case Series
  • Bone Toxicity Case Report Combining Encorafenib, Cetuximab and WNT974 in a Phase I Trial
  • Assessment of Breakthrough Cancer Pain Among Female Patients With Cancer: Knowledge, Management and Characterization in the IOPS-MS Study
Show more Clinical Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire